Lymphoma  >>  Zykadia (ceritinib)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zykadia (ceritinib) / Novartis
SEQUIA, NCT04647110: Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Completed
N/A
549
Europe
crizotinib, alectinib, brigatinib, ceritinib, lorlatinib
Pfizer
ALK-positive NSCLC
03/21
03/21

Download Options